CION Ameerpet
BRCA1 and BRCA2 are two genes that everyone carries — their normal job is to repair damaged DNA and protect against cancer. When one of them carries an inherited fault (a mutation), that protection is weakened, sharply raising the lifetime risk of breast and ovarian cancer. This is the most common cause of hereditary breast cancer. Knowing your BRCA status can change your screening, your prevention options and even your treatment. This page goes deeper into the biology than our practical BRCA gene test guide, which is the companion page on how testing actually works. At CION, a woman-led, tumour-board team helps you understand what a BRCA result means for you and your family.
BRCA1 and BRCA2 (short for BReast CAncer gene 1 and 2) are genes that every person has, inherited from both parents. Far from being "cancer genes", their normal role is the opposite: they are tumour suppressor genes that help repair damaged DNA and keep cell growth under control. When they work properly, they actively protect against cancer.
The problem arises when a person inherits a faulty copy — a mutation — in BRCA1 or BRCA2. With one repair gene already weakened from birth, cells are less able to fix the genetic damage that builds up over a lifetime, and cancer becomes much more likely. This is the most common cause of hereditary breast cancer, and it also raises the risk of ovarian and some other cancers. Importantly, only about 5–10% of all breast cancers are caused by inherited mutations like these — most breast cancer is not hereditary. If you want to know how testing is done in practice, our BRCA gene test page is the companion guide.
BRCA1 and BRCA2 are DNA-repair (tumour suppressor) genes. Working copies guard against cancer — the risk comes from inheriting a faulty version.
Both BRCA1 and BRCA2 mutations sharply raise breast and ovarian cancer risk. They differ in some details — BRCA1 is more linked to triple-negative cancers, for example.
Inherited mutations cause only a small minority of breast cancers. Most breast cancer is not hereditary — but where BRCA is involved, the implications are large.
A woman who carries a BRCA1 or BRCA2 mutation has a much higher lifetime risk of breast cancer than the general population — estimates commonly range from around 45% to 72% by age 70–80, depending on the gene and the study, compared with roughly 12% for an average woman. BRCA mutations also raise the risk of ovarian cancer substantially. Source: NCCN; published BRCA penetrance estimates.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
A BRCA mutation does not guarantee cancer, but it raises the lifetime risk well above average — and not only for breast cancer. The exact numbers vary between BRCA1 and BRCA2 and between studies, but the overall pattern is consistent. Understanding which cancers are involved is what makes targeted screening and prevention possible.
Lifetime breast cancer risk for a carrier is commonly estimated at around 45–72% by age 70–80, versus roughly 12% for an average woman. Carriers also tend to develop breast cancer younger.
BRCA mutations substantially raise the risk of ovarian (and fallopian tube) cancer — higher with BRCA1 than BRCA2. This is a major reason risk-reducing removal of the ovaries is discussed with carriers.
Carriers who have already had breast cancer are at notably higher risk of a new cancer in the other breast over time — which is why a BRCA result can influence surgery choices.
BRCA1-related breast cancers are often triple-negative — a more aggressive subtype. This link is one reason every triple-negative patient is offered BRCA testing.
BRCA2 in particular raises the risk of prostate and pancreatic cancer, and of male breast cancer. BRCA mutations affect men as well as women — and men can pass them on.
A mutation increases the odds — it is not a diagnosis. Many carriers never develop cancer, and the point of knowing is to use screening and prevention to push the odds back down.
BRCA mutations follow a clear inheritance pattern, and understanding it helps you and your relatives make sense of your family history. The mutation is passed down through families and does not skip generations in the way many people assume — which is why a family tree, not just a hunch, guides testing.
BRCA mutations are inherited in an "autosomal dominant" way: each child of a carrier has a 1-in-2 (50%) chance of inheriting the faulty gene, regardless of the child's sex.
A BRCA mutation can be inherited from your mother or your father. Because men carry these genes too, a strong cancer history on your father's side is just as relevant.
If you have inherited the mutation, you can pass it on; if you have not, you cannot pass it to your children. It may appear to "skip" a generation only because a carrier didn't develop cancer — the gene was still there.
Men can carry and transmit BRCA mutations, and BRCA2 raises their own risk of male breast cancer and prostate cancer. Don't overlook the male side of the family.
Not everyone needs a BRCA test — testing is most useful when there are signs that an inherited mutation may be present. Guidelines point to specific features in your personal or family history. Testing always begins with genetic counselling, so you understand what a result will, and will not, tell you before you decide. The step-by-step practicalities are covered on our BRCA gene test page.
A breast cancer diagnosis before about 45–50, or any triple-negative breast cancer before 60, is a recognised reason to be offered BRCA testing.
Several relatives with breast or ovarian cancer, especially diagnosed young or on the same side of the family, raises the chance that a BRCA mutation is running through your family.
Breast and ovarian cancer in the same person, or in close relatives, is a classic pattern of hereditary breast and ovarian cancer syndrome and a strong indication for testing.
If a relative has already tested positive for a specific BRCA mutation, you can be tested precisely for that change — a simpler, targeted test that tells you whether you inherited it.
A male relative with breast cancer is an important clue to an inherited BRCA2 mutation and a reason to consider testing on that side of the family.
A BRCA conversation touches your treatment, your future health, and your family — so it deserves more than a quick test result handed over without explanation. CION is a woman-headed, tumour-board-led organisation that pairs genetic testing with real counselling, so you understand what your result means and what to do next.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Woman-led, tumour-board-reviewed genetic counselling and BRCA care across 35+ centres in Telangana & AP. Call 1800-202-8726.
A positive result — meaning a harmful BRCA1 or BRCA2 mutation has been found — is information, not a sentence. It tells you that your risk is higher than average, and crucially, it opens up powerful ways to manage that risk. Carriers have three broad avenues, used in different combinations depending on age, whether you have already had cancer, and your own preferences: enhanced screening, risk-reducing options, and, if you currently have cancer, BRCA-directed treatment.
None of these is forced on anyone. The right path is decided with you through genetic counselling and specialist discussion, and it can change over time — many women start with intensive screening and consider risk-reducing surgery later. Our prevention page covers these options in more depth.
A BRCA result is not always a simple "yes" or "no". Understanding the different kinds of result — and their limits — prevents both false reassurance and needless worry. This is exactly why testing should come with genetic counselling, so the result is interpreted in the context of your family history rather than in isolation.
A BRCA result is rarely only about you. Because the mutation is inherited, a positive result has direct implications for your blood relatives — your children, siblings and sometimes parents, aunts, uncles and cousins. This can feel like a heavy responsibility, but it is also an opportunity: identifying a mutation lets at-risk relatives test, screen and take action early, turning your result into protection for the people you love. When breast cancer in these families is caught early, outcomes are excellent — and at CION, early-detected breast cancer outcomes run well ahead of the national average.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Whether you are simply curious about your genes, have a strong family history, or have just received a BRCA result, you do not have to make sense of it alone. CION offers a clear, woman-led pathway from question to plan — counselling, testing and action — with your first consultation free.
A specialist reviews your personal and family history, explains what BRCA1 and BRCA2 mean for you, and discusses whether testing is worthwhile — in plain language, without pressure.
If testing is right for you, we provide genetic counselling before and after, and arrange the BRCA gene test — with up to 50% discounts on diagnostics.
We explain exactly what your result means and, with the tumour board, build a plan — enhanced screening, risk-reducing options, or BRCA-directed treatment if you have cancer.
We help you understand cascade testing so at-risk relatives can make their own informed choices — and we stay available as your needs change over time.
Hear from patients treated at CION — diagnosis, treatment path, and where they are today.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.BRCA1 and BRCA2 (BReast CAncer genes 1 and 2) are genes that everyone carries, inherited from both parents. Their normal job is protective: they are tumour suppressor genes that help repair damaged DNA and keep cell growth in check. The risk comes when a person inherits a faulty copy — a mutation — in one of them. With a repair gene already weakened from birth, cells are less able to fix the genetic damage that accumulates over life, so cancer becomes much more likely. A BRCA mutation is the most common cause of hereditary breast cancer and also raises the risk of ovarian and some other cancers. Only about 5–10% of all breast cancers are caused by such inherited mutations.
Substantially. A woman who carries a harmful BRCA1 or BRCA2 mutation has a much higher lifetime risk of breast cancer than average — estimates commonly range from around 45% to 72% by age 70–80, depending on the gene and study, compared with roughly 12% for an average woman. Carriers also tend to develop breast cancer at a younger age, are at higher risk of a second breast cancer, and have a substantially raised risk of ovarian cancer. BRCA1 is more often linked to triple-negative breast cancer. Importantly, a mutation raises the odds but does not guarantee cancer — many carriers never develop it, which is why screening and prevention matter.
BRCA mutations are passed down in an autosomal dominant pattern. This means each child of a carrier has a 1-in-2 (50%) chance of inheriting the faulty gene, regardless of the child's sex. The mutation can be inherited from either your mother or your father — because men carry these genes too, a strong cancer history on the father's side is just as relevant. It does not truly skip generations: it may only appear to, if a carrier in between did not develop cancer. Men can carry and transmit BRCA mutations, and BRCA2 in particular raises a man's own risk of male breast cancer and prostate cancer.
Testing is most useful when there are signs an inherited mutation may be present. Recognised reasons include: breast cancer diagnosed at a young age (before about 45–50), any triple-negative breast cancer before 60, a strong family history of breast or ovarian cancer (especially diagnosed young or on one side of the family), breast and ovarian cancer in the same person or close relatives, a male relative with breast cancer, or a known BRCA mutation already identified in a relative. Testing should always begin with genetic counselling so you understand what a result will and will not tell you. Our BRCA gene test page covers the practical steps; this page explains the genes themselves.
A positive result means a harmful BRCA1 or BRCA2 mutation has been found, so your cancer risk is higher than average. It is information, not a sentence — and it opens up powerful ways to manage risk. Carriers can choose enhanced screening (typically annual breast MRI plus mammography, often starting younger), risk-reducing options (endocrine medication, and surgery such as preventive mastectomy or removal of the ovaries and tubes), and — if you currently have BRCA-related cancer — BRCA-directed treatment with PARP-inhibitor tablets. None of these is forced; the right path is decided with you through counselling, and it can evolve over time. Many women start with intensive screening and consider surgery later.
This page explains the biology and meaning of BRCA1 and BRCA2 in depth — what the genes do, how mutations raise breast and ovarian cancer risk, how the mutation is inherited, who should consider testing, what positive, negative and uncertain results mean, and the implications for your family. Our BRCA gene test page is the practical companion: it focuses on how to actually get tested — the process, the sample, the cost, what to expect, and how results are reported. If you want to understand what BRCA is and what a result means, start here. If you have decided you want to test and want to know how, the BRCA gene test page is the next step. Both work alongside genetic counselling.
Yes. If you currently have breast cancer and are found to carry a BRCA1 or BRCA2 mutation, the result can directly change your treatment. It can make you eligible for targeted therapy with PARP-inhibitor tablets, which exploit the specific DNA-repair weakness in BRCA-mutated cancer cells — an option that is only available if your BRCA status is known. A positive result may also influence your surgery decision, because carriers have a higher risk of a future second breast cancer, which some women weigh when choosing between breast-conserving surgery and mastectomy. This is one reason guidelines recommend BRCA testing for people with triple-negative breast cancer and other higher-risk situations.
Yes. CION offers a free first consultation for all cancer patients and for people who want to understand their inherited risk. In a full 45-minute consultation, a specialist reviews your personal and family history, explains what BRCA1 and BRCA2 mean for you, and discusses whether testing is worthwhile. We provide genetic counselling before and after testing, arrange the BRCA gene test with up to 50% discounts on diagnostics, and translate your result into a clear plan — enhanced screening, risk-reducing options, or BRCA-directed treatment — reviewed by a tumour board. We also help you understand cascade testing for relatives. You can book on 1800-202-8726 or request a callback through the form on this page.
Browse our complete guide to breast cancer — types, symptoms, tests and treatments. Tap any topic to read more.